Laurus Labs Hyderabad unit clears USFDA inspection

Image
Last Updated : Sep 14 2024 | 5:04 PM IST

The inspection concluded with zero 483 observations by the US drug regulator.

The pharmaceutical company said that its API manufacturing facility located at Hyderabad has completed the United States Food and Drug Administration (USFDA) inspection without any 483 observation.

The USFDA conducted the inspection from 9 September 2024 to 13 September 2024.

Laurus Labs' API manufacturing facility, located at DS-1, IKP Knowledge Park, Genome Valley, Shameerpet, Telangana is instrumental in developing active pharmaceutical ingredients, bolstering the companys ability to deliver high-quality, innovative pharmaceutical solutions to its global customers.

Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral, oncology drugs, cardiovascular, gastro and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations, provide contract research and manufacturing services (CRAMS) to global pharma companies.

The companys consolidated net profit dropped 49.7% to Rs 12.51 crore in Q1 FY24 as against Rs 24.85 crore reported in Q1 FY24. Net sales was at Rs 1,194.91 crore in Q1 FY25, up 1.1% from Rs 1,181.79 crore recorded in the same period a year ago.

Shares of Laurus Labs shed 0.25% to settle at Rs 505.70 on Friday, 13 September 2024.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 14 2024 | 4:55 PM IST

Next Story